超声引导经皮消融治疗肾上腺转移瘤的有效性与安全性:Meta分析
该系统评价纳入2000年1月至2022年8月间7项研究共140例肾上腺转移瘤患者,评估超声引导经皮消融的有效性与安全性。汇总分析显示首次和二次技术成功率分别为85%和99%,1年总生存率83%,1年局部肿瘤控制率83%,术中高血压危象发生率14%,主要并发症发生率3.6%。结论认为超声引导经皮消融对肾上腺转移瘤有效且安全。
要点
- 超声引导经皮消融治疗肾上腺转移瘤二次技术成功率可达99%,1年局部控制率83%。
- 术中高血压危象发生率14%,主要并发症发生率3.6%,需重视围术期血压监测。
- 消融方式(RFA vs MWA)和平均肿瘤大小可能是异质性来源。
核心结论
- 超声引导经皮消融治疗肾上腺转移瘤在总生存率、技术成功率和局部控制方面有效且安全。
研究设计与样本
- 系统检索PubMed、Cochrane、Web of Science和Embase数据库,纳入2000年1月至2022年8月发表的7项研究,共140例患者。
- 采用随机效应和固定效应模型进行Meta分析,评估首次和二次技术成功率、1年总生存率、1年局部肿瘤控制率、术中高血压危象发生率和主要并发症。
- 亚组分析探索异质性来源,发现平均肿瘤大小和消融类型与较低异质性相关。
诊断标准与关键数值
- 首次技术成功率85%(95%CI 73-96),二次技术成功率99%(95%CI 96-100)。
- 1年总生存率83%(95%CI 71-93),1年局部肿瘤控制率83%(95%CI 75-90)。
- 术中高血压危象发生率14%(95%CI 8-20),主要并发症总发生率3.6%。
- 140例患者中51例(36.43%)接受射频消融,89例(63.57%)接受微波消融。
临床应用与阅片要点
- 超声引导经皮消融可作为肾上腺转移瘤的微创治疗选择,二次技术成功率高提示必要时可重复消融。
- 术中高血压危象发生率14%,操作中应加强血压监测并做好应急预案。
- 消融类型和肿瘤大小可能影响异质性,选择消融方式和评估肿瘤大小对预后有参考价值。
局限性
- 纳入研究数量较少(7项),样本量有限(140例),可能影响结果的稳健性。
- 研究间存在异质性,亚组分析仅部分解释异质性来源。
- 未报告纳入研究的设计类型、中心数及具体设备/序列信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To assess the efficacy and safety of ultrasound-guided percutaneous ablation (US-PA) for adrenal metastases (AMs) using a meta-analysis.
METHODS: A systematic search of PubMed, Cochrane, Web of Science, and Embase electronic databases was performed to identify studies on US-PA for AM. Seven studies published between January 2000 and August 2022 were analyzed, which resulted in a sample size of 140 patients. Both random effects and common effects meta-analysis models were used to analyze the following efficacy and safety outcomes: the first and secondary technical success rate, 1-year overall survival rates, 1-year local tumor control rate, incidence rate of intraoperative hypertensive crises, and major complications. The subgroup analysis was performed to explore the origin of heterogeneity.
RESULTS: Among 140 patients from 7 studies included in this meta-analysis: 51 (36.43%) underwent radiofrequency ablation (RFA), and 89 (63.57%) underwent microwave ablation (MWA). Pooled data analysis revealed that the first and secondary technical success rates were 85% (95% confidence interval [CI], 73-96) and 99% (95% CI, 96-100), the 1-year overall survival rate was 83% (95% CI, 71-93), the 1-year local tumor control rate was 83% (95% CI, 75-90), and the incidence rate of intraoperative hypertensive crises was 14% (95% CI, 8-20). The overall rate of major complications was 3.6%. In the subgroup analysis, lower heterogeneity was indicated to be associated with mean tumor size and ablation type.
CONCLUSIONS: This meta-analysis showed that US-PA can be both effective and safe for AM in terms of overall survival, technical success rate, and local control for AM.
引用
- Zhong, Wang, Liu, et al. Efficacy and Safety of Ultrasound-Guided Percutaneous Ablation for Adrenal Metastases: A Meta-Analysis. J Ultrasound Med. 2023. PMID: 36840701. doi:10.1002/jum.16198
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。